Article ; Online: Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model.
2010 Volume 15, Issue 1, Page(s) 71–81
Abstract: ... agent based on VAHS pathogenesis. Peroxisome proliferator activated receptor (PPAR) agonists, regulators ... Background: Virus-associated haemophagocytic syndrome (VAHS) is a fatal complication of viral ... papio (HVP)-infected rabbit model. Various doses of rosiglitazone were orally administered to rabbits ...
| Abstract | Background: Virus-associated haemophagocytic syndrome (VAHS) is a fatal complication of viral infections, such as Epstein-Barr virus and H5N1 influenza, that results from macrophage activation and pro inflammatory cytokine injuries. The high comorbidity and mortality of current therapy urgently demands an ideal agent based on VAHS pathogenesis. Peroxisome proliferator activated receptor (PPAR) agonists, regulators of metabolic syndrome, can exhibit immunomodulatory effects on macrophage activation and cytokine secretion. Methods: In this study, we adopted rosiglitazone, a PPAR-gamma agonist, for VAHS control in a Herpesvirus papio (HVP)-infected rabbit model. Various doses of rosiglitazone were orally administered to rabbits on day 7 or day 20 after intravenous challenge with 5 x 10(7) copies of HVP. Results: The rabbits that received 4 mg/day rosiglitazone had significantly increased survival when treated at an early stage of infection (P<0.01), whereas a higher dose (8 mg/day) was required at the advanced stage of the disease (P<0.05). All rosiglitazone-treated rabbits had significantly improved laboratory parameters and plasma tumour necrosis factor-alpha levels. Importantly, rosiglitazone could also inhibit viral replication in vitro and in vivo. Conclusions: PPAR agonists could represent a potentially new agent for the therapy of VAHS. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Administration, Oral ; Animals ; Callithrix ; Cell Line ; Dose-Response Relationship, Drug ; Herpesviridae Infections/blood ; Herpesviridae Infections/complications ; Herpesviridae Infections/virology ; Herpesvirus 4, Human/drug effects ; Herpesvirus 4, Human/physiology ; Humans ; Hypoglycemic Agents/administration & dosage ; Lymphohistiocytosis, Hemophagocytic/blood ; Lymphohistiocytosis, Hemophagocytic/drug therapy ; Lymphohistiocytosis, Hemophagocytic/etiology ; PPAR gamma/agonists ; Rabbits ; Simplexvirus/drug effects ; Simplexvirus/physiology ; Thiazolidinediones/administration & dosage ; Treatment Outcome ; Tumor Necrosis Factor-alpha/blood ; Viral Load/drug effects ; Virus Replication/drug effects | ||||||||||
| Chemical Substances | Hypoglycemic Agents ; PPAR gamma ; Thiazolidinediones ; Tumor Necrosis Factor-alpha ; rosiglitazone (05V02F2KDG) | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2010 | ||||||||||
| Publishing country | England | ||||||||||
| Document type | Journal Article ; Research Support, Non-U.S. Gov't | ||||||||||
| ZDB-ID | 1339842-8 | ||||||||||
| ISSN | 2040-2058 ; 1359-6535 | ||||||||||
| ISSN (online) | 2040-2058 | ||||||||||
| ISSN | 1359-6535 | ||||||||||
| DOI | 10.3851/IMP1490 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4877: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 174: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.